Dupilumab sustains improvements in clinical efficacy and reductions in OCS use in patients with severe, OCS-dependent asthma: LIBERTY ASTHMA TRAVERSE study

Hye Yun Park; Mark Gurnell; Christian  Domingo; Klaus F Rabe; Andrew Menzies-Gow; David Price; Guy  Brusselle; Michael E Wechsler; Changming  Xia; Nami  Pandit-Abid; Rebecca Gall; Juby A.  Jacob-Nara; Paul J.  Rowe; Yamo  Deniz; Shahid  Siddiqui

doi:10.1111/resp.14433

Dupilumab sustains improvements in clinical efficacy and reductions in OCS use in patients with severe, OCS-dependent asthma: LIBERTY ASTHMA TRAVERSE study

Hye Yun Park, Mark Gurnell, Christian Domingo, Klaus F Rabe, Andrew Menzies-Gow, David Price, Guy Brusselle, Michael E Wechsler, Changming Xia, Nami Pandit-Abid, Rebecca Gall, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz, Shahid Siddiqui

Research output: Contribution to journal › Abstract › peer-review

Original language	English
Pages (from-to)	3-413
Number of pages	1
Journal	Respirology
Volume	28
Issue number	S1
Early online date	26 Feb 2023
DOIs	https://doi.org/10.1111/resp.14433
Publication status	Published - 26 Feb 2023
Event	APSR 2022: The 26th Congress of the Asian Pacific Society of Respirology - Coex, Seoul, Korea, Republic of Duration: 17 Nov 2022 → 20 Nov 2022 Conference number: 26 https://apsr2022.org/ http://www.apsr2022.org/

Access to Document

10.1111/resp.14433Licence: Unspecified

Cite this

Park, H. Y., Gurnell, M., Domingo, C., Rabe, K. F., Menzies-Gow, A., Price, D., Brusselle, G., Wechsler, M. E., Xia, C., Pandit-Abid, N., Gall, R., Jacob-Nara, J. A., Rowe, P. J., Deniz, Y., & Siddiqui, S. (2023). Dupilumab sustains improvements in clinical efficacy and reductions in OCS use in patients with severe, OCS-dependent asthma: LIBERTY ASTHMA TRAVERSE study. Respirology, 28(S1), 3-413. https://doi.org/10.1111/resp.14433

Park, HY, Gurnell, M, Domingo, C, Rabe, KF, Menzies-Gow, A, Price, D, Brusselle, G, Wechsler, ME, Xia, C, Pandit-Abid, N, Gall, R, Jacob-Nara, JA, Rowe, PJ, Deniz, Y & Siddiqui, S 2023, 'Dupilumab sustains improvements in clinical efficacy and reductions in OCS use in patients with severe, OCS-dependent asthma: LIBERTY ASTHMA TRAVERSE study', Respirology, vol. 28, no. S1, pp. 3-413. https://doi.org/10.1111/resp.14433

@article{b34ef2ddf4ce43a3a0cf22c4685dc31c,

title = "Dupilumab sustains improvements in clinical efficacy and reductions in OCS use in patients with severe, OCS-dependent asthma: LIBERTY ASTHMA TRAVERSE study",

author = "Park, {Hye Yun} and Mark Gurnell and Christian Domingo and Rabe, {Klaus F} and Andrew Menzies-Gow and David Price and Guy Brusselle and Wechsler, {Michael E} and Changming Xia and Nami Pandit-Abid and Rebecca Gall and Jacob-Nara, {Juby A.} and Rowe, {Paul J.} and Yamo Deniz and Shahid Siddiqui",

year = "2023",

month = feb,

day = "26",

doi = "10.1111/resp.14433",

language = "English",

volume = "28",

pages = "3--413",

journal = "Respirology",

issn = "1323-7799",

publisher = "Wiley",

number = "S1",

note = "APSR 2022 : The 26th Congress of the Asian Pacific Society of Respirology , APSR 2022 ; Conference date: 17-11-2022 Through 20-11-2022",

url = "https://apsr2022.org/, http://www.apsr2022.org/",

}

TY - JOUR

T1 - Dupilumab sustains improvements in clinical efficacy and reductions in OCS use in patients with severe, OCS-dependent asthma

T2 - APSR 2022

AU - Park, Hye Yun

AU - Gurnell, Mark

AU - Domingo, Christian

AU - Rabe, Klaus F

AU - Menzies-Gow, Andrew

AU - Price, David

AU - Brusselle, Guy

AU - Wechsler, Michael E

AU - Xia, Changming

AU - Pandit-Abid, Nami

AU - Gall, Rebecca

AU - Jacob-Nara, Juby A.

AU - Rowe, Paul J.

AU - Deniz, Yamo

AU - Siddiqui, Shahid

N1 - Conference code: 26

PY - 2023/2/26

Y1 - 2023/2/26

U2 - 10.1111/resp.14433

DO - 10.1111/resp.14433

M3 - Abstract

SN - 1323-7799

VL - 28

SP - 3

EP - 413

JO - Respirology

JF - Respirology

IS - S1

Y2 - 17 November 2022 through 20 November 2022

ER -